research The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
Search
for
Sort by
Research
570-600 / 1000+ results
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research Cyclin-dependent kinase inhibitors, p21waf1/cip1 and p27kip1, are expressed site- and hair cycle-dependently in rat hair follicles
p21waf1/cip1 and p27kip1 help in hair follicle differentiation in rats.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Synergistic Antioxidant-Antimicrobial-Immunomodulatory Self-Healing “Radical Sponge” Hydrogel for Diabetic Wound Regeneration via Microenvironment Reprogramming Mediated by Coordinated MAPK Suppression and PI3K-AKT Activation
research Synergistic Antioxidant-Antimicrobial-Immunomodulatory Self-Healing “Radical Sponge” Hydrogel for Diabetic Wound Regeneration via Microenvironment Reprogramming Mediated by Coordinated MAPK Suppression and PI3K-AKT Activation
research Synergistic Antioxidant-Antimicrobial-Immunomodulatory Self-Healing “Radical Sponge” Hydrogel for Diabetic Wound Regeneration via Microenvironment Reprogramming Mediated by Coordinated MAPK Suppression and PI3K-AKT Activation
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study
5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
research IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
Three compounds from Dadap leaves may help treat hair loss.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Re‐Innovation in Clinical Trial Designs Based on Precision Therapy
Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
research Use of Single‐Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma
T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.
research Synthesis and biological activity evaluation of new isatin-gallate hybrids as antioxidant and anticancer agents (in vitro) and in silico study as anticancer agents and coronavirus inhibitors
New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis
Combining ciclosporin and simvastatin can cause severe kidney damage.
research Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research Macrolide Antibiotics (Milestones in Drug Therapy series)
research 471 Senolytic Potential of Fisetin and ABT Compounds in Dermal Fibroblasts
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Predstanormix Duo – a new domestic combination drug for the treatment of lower urinary tract dysfunction symptoms associated with BPH.
Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
research Molecular mechanism of polygonum multiflorum in the treatment of androgenic alopecia: based on bioinformatics and molecular docking method
Polygonum multiflorum may treat hair loss by reducing inflammation and stress, and boosting melanin.
research Dihydrotestosteron und die Rolle der 5α-Reduktasehemmer bei der benignen Prostatahyperplasie
A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.